Opaganib is under clinical development by RedHill Biopharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Autosomal dominant polycystic kidney disease (ADPKD) is the most common, potentially lethal genetic disorder characterized by the progressive enlargement of numerous fluid-filled cysts and the ...